Using organoid testing to find effective treatments for advanced thyroid cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of organoid-based drug screening to guide targeted therapy for patients with locally advanced thyroid cancer. Participants will receive medications identified as sensitive through organoid testing, and the study will measure tumor size changes and survival outcomes. Additionally, the trial will analyze various factors that may influence the effectiveness of these treatments, including tumor characteristics and patient demographics. The goal is to determine if this personalized approach can improve treatment outcomes and reduce surgical risks for patients with advanced disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Adult participants who have either been initially diagnosed with locally advanced thyroid cancer or have experienced persistent or recurrent thyroid cancer, including cervical nodal recurrence. Types of pathology include:

  1. Papillary thyroid carcinoma (PTC)
  2. Follicular thyroid carcinoma (FTC)
  3. Medullary thyroid carcinoma (MTC)
  4. Poorly differentiated thyroid carcinoma (PDTC)
  5. Anaplastic thyroid carcinoma (ATC)
* 2\. Evidence of extrathyroidal extension and/or locally invasive disease and deemed at risk for R2 resection by treating team on clinical and/or fiberoptic examination and/or radiographic evaluation in the primary or recurrent setting. Evidence of "at risk for R2 resection" includes:

  1. Vocal cord paralysis by fiberoptic examination
  2. Extrathyroid and/or extranodal extension on CT or MRI, including tracheal and/or laryngeal cartilage invasion, esophageal involvement, and/or involvement of perithyroid muscles (e.g. strap, sternocleidomastoid, inferior constrictor muscles) or bone involvement
  3. Extension into the mediastinum with visceral and/or vascular involvement
  4. Involvement of the carotid artery or other major vessel by 180 degrees or more
  5. Other factors that make the participant to be "at risk for R2 resection" may be allowed, after discussion with the study's principal investigator.
* 3\. There is at least one measurable lesion according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST).
* 4\. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
* 5\. Normal organ and bone marrow function.
* 6\. Adequate end-organ function (including bone marrow, coagulation, renal, liver and cardiac) 28 days prior to the study registration.
* 7\. Ability to swallow pills.
* 8\. Signed informed consent form.
* 9\. Expected survival time of more than 2 months.

Exclusion Criteria:

* 1\. Patients with contraindications specified in the drug instructions for the targeted drugs involved in the corresponding organoid drug sensitivity tests.
* 2\. Patients with incomplete clinical data.
* 3\. Patients with severe organ dysfunction, metabolic diseases, or other conditions significantly affecting survival.
* 4\. Other active malignant disease requiring therapy.
* 5\. Females who are pregnant or breastfeeding.
* 5\. Patients without target lesions.
* 6\. Patients deemed unsuitable for inclusion by the researchers.

Where it's running

• West China hospital
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Zhihui Li, Professor
• Email: rockoliver@vip.sina.com
• Phone: 18980602027

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant Cryo-Thermal Ablation with Toripalimab and Chemo for Resectable NSCLC

  This study tests whether using Cryo-Thermal Ablation before chemo-immunotherapy helps people with resectable NSCLC see better outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan and 8 other locations · NCT07855965

• Tai Chi during radiotherapy for head and neck cancer fatigue

  This trial tests whether a 12-week Yang-style Tai Chi program added to usual care can reduce cancer-related fatigue in adults with head and neck cancer undergoing radiotherapy.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809776

• Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery

  This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809763

• First-line combo therapy with GnP, SHR-1701, and Apatinib for metastatic pancreatic cancer

  This trial tests whether adding SHR-1701 and Apatinib to standard GnP can safely and effectively treat previously untreated metastatic pancreatic cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07802184

• Early warning and stratified diagnosis of postoperative respiratory failure using ventilator waveform features

  This study tests whether patterns in ventilator waveforms can predict and categorize risk of breathing failure after surgery for adults on mechanical ventilation.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07799636

• JWK001 subretinal therapy for neovascular AMD

  This study tests a single subretinal dose of JWK001 at different levels in people with wet age-related macular degeneration who have previously responded to anti-VEGF treatment.

  Recruiting at 2 sites Phase 2 West China Hospital · Beijing, Beijing Municipality and 15 other locations · NCT07776522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.